 LEXINGTON, Mass.--BUSINESS WIRE--Cyteir Therapeutics, Inc. Cyteir Nasdaq: CYT, a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the closing of its initial public offering of 7,400,000 shares of its common stock at an initial public offering price of 18.00 per share. All of the shares are being offered by Cyteir. In addition, Cyteir has granted the underwriters a 30-day option to purchase up to an additional 